Researchers track thousands of pregnancies to compare safety of two common eczema treatments
NCT ID NCT06627335
Summary
This study aims to understand the safety of a newer eczema cream (ruxolitinib) during pregnancy by comparing it to standard steroid creams. Researchers will analyze health insurance claims data from over 5,600 pregnant women in the US who have atopic dermatitis (eczema). The study will track pregnancy outcomes and infant health for up to one year after birth to look for any differences between the two treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Syneos Health (remote site)
RECRUITINGMorrisville, North Carolina, 27560, United States
Conditions
Explore the condition pages connected to this study.